Cargando…
The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study
INTRODUCTION: This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients. METHODS: A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071681/ https://www.ncbi.nlm.nih.gov/pubmed/27020720 http://dx.doi.org/10.1111/appy.12238 |
| _version_ | 1782461305948471296 |
|---|---|
| author | Liang, Ying Cao, Changan Zhu, Cheng Wang, Chuanyue Zhang, Congpei Dong, Fang Yang, Fude Deng, Hong Yu, Jingjie Tang, Jisheng Su, Lei Xin, Limin Hong, Ling Gao, Minglong Tang, Muni Xie, Shiping Lu, Shuiping Liu, Tiebang Xu, Xiaojin Wang, Xijin Li, Xuanzi Wang, Xueyi Li, Yi Zhang, Yong Chen, Zhiyu Yu, Xin |
| author_facet | Liang, Ying Cao, Changan Zhu, Cheng Wang, Chuanyue Zhang, Congpei Dong, Fang Yang, Fude Deng, Hong Yu, Jingjie Tang, Jisheng Su, Lei Xin, Limin Hong, Ling Gao, Minglong Tang, Muni Xie, Shiping Lu, Shuiping Liu, Tiebang Xu, Xiaojin Wang, Xijin Li, Xuanzi Wang, Xueyi Li, Yi Zhang, Yong Chen, Zhiyu Yu, Xin |
| author_sort | Liang, Ying |
| collection | PubMed |
| description | INTRODUCTION: This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients. METHODS: A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. RESULTS: A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events. DISCUSSION: Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia. |
| format | Online Article Text |
| id | pubmed-5071681 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-50716812016-11-02 The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study Liang, Ying Cao, Changan Zhu, Cheng Wang, Chuanyue Zhang, Congpei Dong, Fang Yang, Fude Deng, Hong Yu, Jingjie Tang, Jisheng Su, Lei Xin, Limin Hong, Ling Gao, Minglong Tang, Muni Xie, Shiping Lu, Shuiping Liu, Tiebang Xu, Xiaojin Wang, Xijin Li, Xuanzi Wang, Xueyi Li, Yi Zhang, Yong Chen, Zhiyu Yu, Xin Asia Pac Psychiatry Brief Reports INTRODUCTION: This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients. METHODS: A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. RESULTS: A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events. DISCUSSION: Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia. John Wiley and Sons Inc. 2016-03-28 2016-09 /pmc/articles/PMC5071681/ /pubmed/27020720 http://dx.doi.org/10.1111/appy.12238 Text en © 2016 The Authors Asia‐Pacific Psychiatry Published by John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Brief Reports Liang, Ying Cao, Changan Zhu, Cheng Wang, Chuanyue Zhang, Congpei Dong, Fang Yang, Fude Deng, Hong Yu, Jingjie Tang, Jisheng Su, Lei Xin, Limin Hong, Ling Gao, Minglong Tang, Muni Xie, Shiping Lu, Shuiping Liu, Tiebang Xu, Xiaojin Wang, Xijin Li, Xuanzi Wang, Xueyi Li, Yi Zhang, Yong Chen, Zhiyu Yu, Xin The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study |
| title | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study |
| title_full | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study |
| title_fullStr | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study |
| title_full_unstemmed | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study |
| title_short | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study |
| title_sort | effectiveness and safety of amisulpride in chinese patients with schizophrenia: an 8‐week, prospective, open‐label, multicenter, single‐arm study |
| topic | Brief Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071681/ https://www.ncbi.nlm.nih.gov/pubmed/27020720 http://dx.doi.org/10.1111/appy.12238 |
| work_keys_str_mv | AT liangying theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT caochangan theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT zhucheng theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT wangchuanyue theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT zhangcongpei theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT dongfang theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT yangfude theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT denghong theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT yujingjie theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT tangjisheng theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT sulei theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT xinlimin theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT hongling theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT gaominglong theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT tangmuni theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT xieshiping theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT lushuiping theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT liutiebang theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT xuxiaojin theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT wangxijin theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT lixuanzi theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT wangxueyi theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT liyi theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT zhangyong theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT chenzhiyu theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT yuxin theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT liangying effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT caochangan effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT zhucheng effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT wangchuanyue effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT zhangcongpei effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT dongfang effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT yangfude effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT denghong effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT yujingjie effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT tangjisheng effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT sulei effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT xinlimin effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT hongling effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT gaominglong effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT tangmuni effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT xieshiping effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT lushuiping effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT liutiebang effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT xuxiaojin effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT wangxijin effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT lixuanzi effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT wangxueyi effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT liyi effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT zhangyong effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT chenzhiyu effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy AT yuxin effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniaan8weekprospectiveopenlabelmulticentersinglearmstudy |